Regeneron Pharmaceuticals, Inc. research snapshot
REGN AI stock analysis reads Regeneron Pharmaceuticals as a founder-led biotechnology company whose second quarter 2026 beat, record Dupixent, EYLEA HD and Libtayo sales, and fully repaid Sanofi development balance have lifted sentiment, while EYLEA erosion, a recent fianlimab Phase III miss, and class-action overhang keep the case event-driven. At the August 2, 2026 data cutoff, REGN closed near $762.63 with an implied market capitalization of about $76.15 billion. This page uses scenario ranges, technical levels, and source-backed facts. It is informational research, not investment advice.
Current price
$762.63
Market cap
$76.15 billion
AI score
74 / 100
Rating
High-quality founder-led biotech with improving growth and event risk
Trend status
Short-term uptrend, long-term trend neutral, overbought after the Q2 earnings rally
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Regeneron monetizes biologic science through approved medicines, Sanofi and Bayer collaboration revenue, in-house product sales, and a pipeline of about 50 active clinical programs. | High |
| Moat | The moat comes from antibody discovery, genetics data, patents, biologics manufacturing, clinical know-how, prescriber trust, and collaboration scale, but EYLEA is being challenged by biosimilar launches. | Medium-high |
| Management | Founder CEO Leonard Schleifer and founding scientist George Yancopoulos remain central to the culture, pipeline, and disciplined capital allocation record. | Medium-high |
| Financial trend | Q2 2026 revenue grew 17% to $4.3 billion and non-GAAP EPS grew 11% to $14.29, with TTM revenue near $15.54 billion; the Sanofi profit share steps up from Q3 2026. | High |
| Valuation | At $762.63, REGN traded near 18.9x TTM GAAP EPS, about 14.7x FY2026E non-GAAP EPS, 4.9x sales, 2.4x book, and 20.3x free cash flow using verified inputs, with about $151 per share of net cash. | Medium-high |
| Technical trend | ChartMill rated technicals 9/10 with a setup score of 1/10, short-term trend up and long-term trend neutral, with RSI near 78 and MACD positive after the Q2 rally. | Medium |
| Risk level | Key risks are EYLEA biosimilar erosion, drug-pricing policy, clinical setbacks such as the fianlimab miss, class-action litigation, manufacturing issues, and leadership succession. | Medium-high |
| AI confidence | High for descriptive research and calculations, lower for exact price outcomes because biotech event risk is nonlinear. | High data confidence |
| Investment certainty | Medium certainty. REGN is a high-quality biotech with improving momentum, but a buy decision depends on price discipline, EYLEA stabilization, pipeline conversion, and litigation developments. | Medium |
REGN AI stock forecast
The REGN AI stock forecast uses scenario math around the $762.63 quote and the FY2026E consensus non-GAAP EPS of $51.73. The three-year framework produced a bearish area near $620, a base area near $1,030, and a bullish area near $1,570 before dividends, while the 27-analyst consensus price target is $833.54 over 12 months.
$1,480 to $1,650
More likely if the Sanofi profit step-up flows through from Q3, Dupixent keeps growing in the high teens, EYLEA HD holds share, Libtayo and rare disease programs scale, obesity and Factor XI programs de-risk, and investors pay about 20x earnings.
$1,000 to $1,080
More likely if earnings compound at high single digits to low teens, EYLEA erosion is offset by Dupixent and EYLEA HD growth, pipeline milestones deliver on time, and the market holds a mid-teens multiple.
$590 to $650
More likely if EYLEA biosimilar erosion accelerates, EYLEA HD faces intensifying competition, drug-pricing policy reduces net prices, more pipeline setbacks follow the fianlimab miss, litigation becomes a lasting overhang, or the multiple compresses to about 11x.
REGN AI technical analysis
REGN AI technical analysis is strong but extended as of the July 31, 2026 close. StockAnalysis listed the stock at $762.63, with a 50-day moving average near $643.68, a 200-day moving average near $709.73, and RSI near 78.05. ChartMill rated technicals 9/10 with a setup score of 1/10, described the short-term trend as up, the long-term trend as neutral, and MACD as positive.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $762.63 | July 31, 2026 close used for the August 2, 2026 data cutoff and market cap math. |
| Near support | $676 to $687 | ChartMill support zone from 676.29 to 686.52, formed by trend lines and moving averages in multiple time frames. |
| Secondary support | $644 to $664 | ChartMill support zone from 643.68 to 663.56, with the 50-day moving average sitting near $643.68. |
| Deep support | $620 to $623 | ChartMill listed a weekly trend-line support area near $622.99. |
| Resistance | $803 to $812 | ChartMill resistance zone from 803.18 to 812.28, just below the 52-week high near $821.11. |
| Momentum | RSI 78.05, MACD +8.84 | RSI and stochastics near 95 are overbought while MACD is positive and rising; ADX near 31.77 signals a strong trend. |
| Volume | Average near 1.01 million shares per day | StockAnalysis lists a 20-day average near 785,487 shares; watch volume spikes around FDA decisions, earnings, and pipeline data. |
| Volatility | Low beta, high event sensitivity | StockAnalysis lists beta near 0.18 and ChartMill ATR near 2.63%, but biotech clinical, FDA, and litigation events can still create sharp single-stock moves. |
| Invalidation | Close below $644, then $623 | A break below the 50-day moving average weakens the uptrend. A break below the $623 weekly trend line would force a fresh thesis review. |
REGN AI trading strategy
The REGN AI trading strategy is a rules-based framework for a cash-rich large-cap biotech with a strong earnings beat, extended technicals, and pipeline plus litigation risk. It is not personal advice and should be paired with live quotes, position sizing, FDA calendars, earnings releases, and risk limits.
REGN is above a rising 50-day moving average near $643.68 and a rising 200-day moving average near $709.73 with a positive MACD. A continuation setup needs the price to hold the $676 to $687 support zone on pullbacks and to confirm strength toward the $803 to $812 resistance.
A close below the $644 area should reduce trend confidence. A close below $623 should invalidate the swing setup and trigger a fundamental review.
With RSI near 78 and stochastics near 95, REGN is short-term overbought. If the stock pulls back toward $676 to $687 or the 50-day moving average without a new product, pricing, trial, or litigation problem, compare the drawdown with Dupixent growth, EYLEA HD share gains, the Sanofi profit step-up, and buyback support.
Do not average down through drug-specific bad news. FDA decisions, biosimilar launches, or trial readouts can turn a chart level into a business-level break.
Track Dupixent global net sales, EYLEA HD versus EYLEA U.S. sales and franchise share, Libtayo growth, Sanofi collaboration profit share, the garetosmab FDA decision in August and cemdisiran decision in November, PNH data in the fourth quarter, EYLEA HD pre-filled syringe approval timing, obesity phase III starts, buybacks, and cash net of debt.
Lower confidence if EPS growth depends mainly on marketable-security gains, multiple expansion, or buybacks rather than product growth and pipeline conversion. Watch the securities class actions tied to clinical-trial disclosures.
Investment research summary
Regeneron converts antibody science, genetics data, clinical proof, biologics manufacturing, regulatory approvals, and partner commercialization into medicine revenue and collaboration economics, with a fully repaid Sanofi development balance that should lift reported collaboration revenue from the third quarter of 2026.
The moat is strongest where VelociSuite antibody technology, the Regeneron Genetics Center, patents, biologics manufacturing, trial execution, and prescriber trust reinforce each other. It weakens when a patent expires, a rival drug is better, or a payer forces price concessions, which is what EYLEA biosimilars are now testing.
The thesis fails if EYLEA and EYLEA HD decline faster than Dupixent, Libtayo, and newer products grow, if more late-stage programs miss after the fianlimab setback, if drug-pricing policy cuts net prices, if the class-action overhang expands, or if founder-led scientific culture becomes hard to replicate.
Leonard Schleifer and George Yancopoulos built Regeneron around internal discovery and long-cycle R&D, and the Q2 call showed disciplined capital allocation with about $2 billion of buybacks in the first half of 2026. The next test is succession planning, business development discipline, and whether pipeline choices keep returns high after the founding era.
Large-cap biotech benefits from aging populations, biologics innovation, genetics data, oncology, immunology, and rare disease demand, but faces patent cliffs, payer scrutiny, biosimilars, FDA risk, and binary clinical outcomes.
REGN is valued as a durable but event-driven biotech, not as a no-risk compounder. At $762.63 it trades near 18.9x TTM GAAP EPS and about 14.7x FY2026E non-GAAP EPS with net cash of about $151 per share, so the margin of safety depends on whether the market is underpricing Dupixent economics and the Sanofi step-up or correctly discounting EYLEA, policy, clinical, and litigation risk after a sharp rally.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| REGN price | $762.63 close on July 31, 2026 | StockAnalysis quote and statistics | August 2, 2026 |
| Market capitalization | $76.15 billion, verified as $762.63 x 99.85 million shares | financial_rigor.py market cap verification | August 2, 2026 |
| TTM revenue and EPS | TTM revenue $15.535 billion up 9.3%; TTM GAAP EPS $40.43, both ended June 30, 2026 | StockAnalysis financials | August 2, 2026 |
| FY2025 revenue and net income | $14.343 billion revenue, $4.505 billion GAAP net income | Regeneron FY2025 release and StockAnalysis | August 2, 2026 |
| Q2 2026 results | Revenue $4.3 billion up 17%; non-GAAP diluted EPS $14.29 up 11%; net income $1.5 billion | Regeneron Q2 2026 earnings release, July 30, 2026 | August 2, 2026 |
| Dupixent Q2 2026 | Global net sales $6.0 billion, up 38% constant currency; U.S. sales $4.6 billion, up 42% | Regeneron Q2 2026 earnings release and call | August 2, 2026 |
| EYLEA HD and EYLEA U.S. Q2 2026 | EYLEA HD $596 million, up 52% year over year; EYLEA $412 million, down 45%; combined U.S. sales just over $1 billion | Regeneron Q2 2026 earnings release and call | August 2, 2026 |
| Libtayo Q2 2026 | Global net sales $489 million, up 29% constant currency; U.S. sales $343 million, up 38% | Regeneron Q2 2026 earnings release and call | August 2, 2026 |
| Cash and marketable securities | $15.1 billion net of debt at June 30, 2026; cash and equivalents $7.99 billion, total debt $2.71 billion | Regeneron Q2 2026 earnings call and StockAnalysis statistics | August 2, 2026 |
| Share count and ownership | 99.85 million shares outstanding; insiders 3.90%; institutions 92.74% | StockAnalysis statistics | August 2, 2026 |
| Valuation ratios | 18.86x TTM GAAP EPS, 12.58x forward PE, 4.90x sales, 2.41x book, 20.25x free cash flow | financial_rigor.py valuation verification | August 2, 2026 |
| Analyst consensus | Buy rating from 27 analysts, average price target $833.54, range $641 to $1,030; FY2026E non-GAAP EPS $51.73 | S&P Global Market Intelligence via StockAnalysis | August 2, 2026 |
| Technical snapshot | 50-day MA $643.68, 200-day MA $709.73, RSI 78.05; ChartMill technical rating 9/10, setup 1/10, short-term trend up, long-term trend neutral | StockAnalysis and ChartMill technical data | August 2, 2026 |
| Capital returns | About $2 billion of buybacks in H1 2026, 2.4 million shares retired, $2.5 billion authorization left; dividend $3.76 per share, 0.49% yield | Regeneron Q2 2026 earnings call and StockAnalysis | August 2, 2026 |
This REGN AI stock analysis is an informational research tool only. It is not investment advice, financial advice, a recommendation, or a guarantee of future returns. Forecast scenarios are based on available public data as of August 2, 2026 and can be wrong.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
